Literature DB >> 20577007

The c.859G>C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor.

S Bernal, L Alías, M J Barceló, E Also-Rallo, R Martínez-Hernández, J Gámez, E Guillén-Navarro, J Rosell, I Hernando, F J Rodríguez-Alvarez, S Borrego, J M Millán, C Hernández-Chico, M Baiget, P Fuentes-Prior, E F Tizzano.   

Abstract

Homozygous mutations of the telomeric SMN1 gene lead to degeneration of motor neurons causing spinal muscular atrophy (SMA). A highly similar centromeric gene (SMN2) can only partially compensate for SMN1 deficiency. The c.859G>C variant in SMN2 has been recently reported as a positive disease modifier. We identified the variant in 10 unrelated chronic SMA patients with a wide spectrum of phenotypes ranging from type II patients who can only sit to adult walkers. Haplotype analysis strongly suggests that the variant originated from a common ancestor. Our results confirm that the c.859G>C variant is a milder SMN2 allele and predict a direct correlation between SMN activity and phenotypic severity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20577007     DOI: 10.1136/jmg.2010.079004

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  37 in total

1.  Splicing regulation in spinal muscular atrophy by an RNA structure formed by long-distance interactions.

Authors:  Natalia N Singh; Brian M Lee; Ravindra N Singh
Journal:  Ann N Y Acad Sci       Date:  2015-02-27       Impact factor: 5.691

Review 2.  Spinal muscular atrophy: state of the art and new therapeutic strategies.

Authors:  Sonia Messina; Maria Sframeli; Lorenzo Maggi; Adele D'Amico; Claudio Bruno; Giacomo Comi; Eugenio Mercuri
Journal:  Neurol Sci       Date:  2021-04-19       Impact factor: 3.307

Review 3.  Advances in therapeutic development for spinal muscular atrophy.

Authors:  Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

4.  Natural history of infantile-onset spinal muscular atrophy.

Authors:  Stephen J Kolb; Christopher S Coffey; Jon W Yankey; Kristin Krosschell; W David Arnold; Seward B Rutkove; Kathryn J Swoboda; Sandra P Reyna; Ai Sakonju; Basil T Darras; Richard Shell; Nancy Kuntz; Diana Castro; Julie Parsons; Anne M Connolly; Claudia A Chiriboga; Craig McDonald; W Bryan Burnette; Klaus Werner; Mathula Thangarajh; Perry B Shieh; Erika Finanger; Merit E Cudkowicz; Michelle M McGovern; D Elizabeth McNeil; Richard Finkel; Susan T Iannaccone; Edward Kaye; Allison Kingsley; Samantha R Renusch; Vicki L McGovern; Xueqian Wang; Phillip G Zaworski; Thomas W Prior; Arthur H M Burghes; Amy Bartlett; John T Kissel
Journal:  Ann Neurol       Date:  2017-12-08       Impact factor: 10.422

5.  Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability.

Authors:  Eva Also-Rallo; Laura Alías; Rebeca Martínez-Hernández; Lidia Caselles; María J Barceló; Montserrat Baiget; Sara Bernal; Eduardo F Tizzano
Journal:  Eur J Hum Genet       Date:  2011-05-25       Impact factor: 4.246

6.  Detection of SMN1 to SMN2 gene conversion events and partial SMN1 gene deletions using array digital PCR.

Authors:  Deborah L Stabley; Jennifer Holbrook; Mena Scavina; Thomas O Crawford; Kathryn J Swoboda; Katherine M Robbins; Matthew E R Butchbach
Journal:  Neurogenetics       Date:  2021-01-07       Impact factor: 2.660

Review 7.  Spinal muscular atrophy: diagnosis and management in a new therapeutic era.

Authors:  W David Arnold; Darine Kassar; John T Kissel
Journal:  Muscle Nerve       Date:  2014-12-16       Impact factor: 3.217

8.  A role for SMN exon 7 splicing in the selective vulnerability of motor neurons in spinal muscular atrophy.

Authors:  Matteo Ruggiu; Vicki L McGovern; Francesco Lotti; Luciano Saieva; Darrick K Li; Shingo Kariya; Umrao R Monani; Arthur H M Burghes; Livio Pellizzoni
Journal:  Mol Cell Biol       Date:  2011-10-28       Impact factor: 4.272

9.  A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy.

Authors:  Xingxing Wu; Shu-Huei Wang; Junjie Sun; Adrian R Krainer; Yimin Hua; Thomas W Prior
Journal:  Hum Mol Genet       Date:  2017-07-15       Impact factor: 6.150

Review 10.  Spinal muscular atrophy: development and implementation of potential treatments.

Authors:  W David Arnold; Arthur H M Burghes
Journal:  Ann Neurol       Date:  2013-09       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.